Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

A model-based approach to dose selection in early pediatric development.

Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O.

Clin Pharmacol Ther. 2010 Mar;87(3):294-302. doi: 10.1038/clpt.2009.234. Epub 2010 Jan 27. Erratum in: Clin Pharmacol Ther. 2010 Jun;87(6):759.

PMID:
20107435
[PubMed - indexed for MEDLINE]
2.

Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study.

Jadhav PR, Zhang J, Gobburu JV.

Pharm Stat. 2009 Jul-Sep;8(3):216-24. doi: 10.1002/pst.394.

PMID:
19610013
[PubMed - indexed for MEDLINE]
3.

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Karlsson MO, Lutsar I, Milligan PA.

Antimicrob Agents Chemother. 2009 Mar;53(3):935-44. doi: 10.1128/AAC.00751-08. Epub 2008 Dec 15.

PMID:
19075073
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

An alternative method for population pharmacokinetic data analysis under noncompliance.

Gupta P, Hutmacher MM, Frame B, Miller R.

J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):219-33. doi: 10.1007/s10928-008-9085-5. Epub 2008 Feb 26.

PMID:
18299967
[PubMed - indexed for MEDLINE]
5.

Mechanism-based concepts of size and maturity in pharmacokinetics.

Anderson BJ, Holford NH.

Annu Rev Pharmacol Toxicol. 2008;48:303-32. Review.

PMID:
17914927
[PubMed - indexed for MEDLINE]
6.

Atazanavir: simplicity and convenience in different scenarios.

Pérez-Elías MJ.

Expert Opin Pharmacother. 2007 Apr;8(5):689-700. Review.

PMID:
17376023
[PubMed - indexed for MEDLINE]
7.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

PMID:
16940065
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
[PubMed - indexed for MEDLINE]
9.

Review of atazanavir: a novel HIV protease inhibitor.

Fuster D, Clotet B.

Expert Opin Pharmacother. 2005 Aug;6(9):1565-72. Review.

PMID:
16086644
[PubMed - indexed for MEDLINE]
10.

Population one-compartment pharmacokinetic analysis with missing dosage data.

Soy D, Beal SL, Sheiner LB.

Clin Pharmacol Ther. 2004 Nov;76(5):441-51.

PMID:
15536459
[PubMed - indexed for MEDLINE]
11.

Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.

Schuster A, Burzawa S, Jemal M, Loizillon E, Couerbe P, Whigan D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 May 25;788(2):377-86.

PMID:
12705978
[PubMed - indexed for MEDLINE]
12.

Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

Kowalski KG, Hutmacher MM.

J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):253-75.

PMID:
11468940
[PubMed - indexed for MEDLINE]
13.

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Yano Y, Beal SL, Sheiner LB.

J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92.

PMID:
11381569
[PubMed - indexed for MEDLINE]
14.

A size standard for pharmacokinetics.

Holford NH.

Clin Pharmacokinet. 1996 May;30(5):329-32. No abstract available.

PMID:
8743333
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk